These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
434 related articles for article (PubMed ID: 24345265)
1. Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia. Boggs DL; Carlson J; Cortes-Briones J; Krystal JH; D'Souza DC Curr Pharm Des; 2014; 20(31):5077-92. PubMed ID: 24345265 [TBL] [Abstract][Full Text] [Related]
2. Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking. Ochoa EL; Lasalde-Dominicci J Cell Mol Neurobiol; 2007 Aug; 27(5):609-39. PubMed ID: 17554626 [TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia. Beinat C; Banister SD; Herrera M; Law V; Kassiou M CNS Drugs; 2015 Jul; 29(7):529-42. PubMed ID: 26242477 [TBL] [Abstract][Full Text] [Related]
5. The nicotinergic receptor as a target for cognitive enhancement in schizophrenia: barking up the wrong tree? Quisenaerts C; Morrens M; Hulstijn W; de Bruijn E; Timmers M; Streffer J; De la Asuncion J; Dumont G; Sabbe B Psychopharmacology (Berl); 2014 Feb; 231(3):543-50. PubMed ID: 24022237 [TBL] [Abstract][Full Text] [Related]
7. Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Martin LF; Freedman R Int Rev Neurobiol; 2007; 78():225-46. PubMed ID: 17349863 [TBL] [Abstract][Full Text] [Related]
8. The potential of nicotinic enhancement of cognitive remediation training in schizophrenia. Hahn B; Gold JM; Buchanan RW Neuropharmacology; 2013 Jan; 64():185-90. PubMed ID: 22705396 [TBL] [Abstract][Full Text] [Related]
9. Nicotine use in schizophrenia: the self medication hypotheses. Kumari V; Postma P Neurosci Biobehav Rev; 2005; 29(6):1021-34. PubMed ID: 15964073 [TBL] [Abstract][Full Text] [Related]
11. α7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia. Ishikawa M; Hashimoto K Curr Pharm Des; 2011; 17(2):121-9. PubMed ID: 21355839 [TBL] [Abstract][Full Text] [Related]
12. Dementia praecox redux: a systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia. Rowe AR; Mercer L; Casetti V; Sendt KV; Giaroli G; Shergill SS; Tracy DK J Psychopharmacol; 2015 Feb; 29(2):197-211. PubMed ID: 25567553 [TBL] [Abstract][Full Text] [Related]
13. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment. Snyder GL; Vanover KE Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266 [TBL] [Abstract][Full Text] [Related]
14. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Hauser TA; Kucinski A; Jordan KG; Gatto GJ; Wersinger SR; Hesse RA; Stachowiak EK; Stachowiak MK; Papke RL; Lippiello PM; Bencherif M Biochem Pharmacol; 2009 Oct; 78(7):803-12. PubMed ID: 19482012 [TBL] [Abstract][Full Text] [Related]
15. Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers. Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V J Psychopharmacol; 2019 Jun; 33(6):688-699. PubMed ID: 30920339 [TBL] [Abstract][Full Text] [Related]
16. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. Zhang XY; Liu L; Liu S; Hong X; Chen DC; Xiu MH; Yang FD; Zhang Z; Zhang X; Kosten TA; Kosten TR Am J Psychiatry; 2012 Sep; 169(9):974-81. PubMed ID: 22952075 [TBL] [Abstract][Full Text] [Related]
17. Procognitive effects of varenicline in the animal model of schizophrenia depend on α4β2- and α 7-nicotinic acetylcholine receptors. Potasiewicz A; Golebiowska J; Popik P; Nikiforuk A J Psychopharmacol; 2018 Dec; 33(1):269881118812097. PubMed ID: 30501536 [TBL] [Abstract][Full Text] [Related]
18. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836 [TBL] [Abstract][Full Text] [Related]
19. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. Levin ED; Rezvani AH Biochem Pharmacol; 2007 Oct; 74(8):1182-91. PubMed ID: 17714691 [TBL] [Abstract][Full Text] [Related]
20. Development of nicotinic drug therapy for cognitive disorders. Levin ED; Rezvani AH Eur J Pharmacol; 2000 Mar; 393(1-3):141-6. PubMed ID: 10771007 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]